

Spago Nanomedical - Tumorad in the spotlight

Redeye comments on Spago's Q4 2022 report, and we estimate that the company is making solid progress towards starting its phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). Further, we judge that patient recruitment to the company's phase IIa trial with SpagoPix (SN132D) is progressing solidly. We make some minor adjustments to our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Spago Nanomedical - Tumorad in the spotlight](#)